布地奈德气雾剂联合氨溴索注射液雾化治疗新生儿肺炎的疗效研究

目的 观察研究布地奈德气雾剂联合氨溴索注射液雾化治疗新生儿肺炎的临床疗效。方法 选取2018年1月—2019年4月在我院治疗的94例新生儿肺炎进行研究,通过随机分组的方式将其分为对照组(45例)和研究组(49例),对照组患儿采取氨溴索注射液雾化治疗,研究组患儿采取布地奈德气雾剂联合氨溴索注射液雾化治疗,研究比较两组患儿的治疗效果、临床症状改善时间以及呼吸指数改善情况等。结果 研究组患儿治疗总有效率为91.84%,高于对照组的68.89%,P<0.05;研究组患儿气喘改善时间(8.15±2.26)d,咳嗽改善时间(8.02±2.10)d,湿啰音改善时间(8.16±1.25)d,呼吸增快改善时间(49.69±6.11)h,紫绀改善时间(35.29±6.52)h,短于对照组的气喘改善时间(3.96±1.88)d,咳嗽改善时间(4.11±1.29)d,湿啰音改善时间(5.13±0.86)d,呼吸增快改善时间(28.92±5.99)h,紫绀改善时间(18.85±4.12)h,差异具有统计学意义 P<0.05;两组患儿PCO2与OI值在治疗之前进行对比P>0.05,PCO2值治疗后与对照组比较明显较低 P<0.05,OI值与对照组比较明显较高P<0.05。结论 对新生儿肺炎患儿采取布地奈德气雾剂联合氨溴索注射液雾化治疗具有显著的疗效,能明显缩短患儿临床症状的改善时间,改善呼吸指数,值得临床应用及推广。

Therapeutic effect of budesonide aerosol combined with ambroxol injection on neonatal pneumonia

Objective To investigate the clinical efficacy of budesonide aerosol combined with ambroxol injection in the treatment of neonatal pneumonia. Methods A total of 94 cases of neonatal pneumonia treated in a hospital from January 2018 to April 2019 were selected and they were randomly divided into a control group (45 cases) and a trial group (49 cases). The patients in the control group were treated with ambroxol injection, and the cases in the trial group were treated with budesonide aerosol and ambroxol injection. The therapeutic effects, clinical symptom improvement time and breathing indexes were investigated and compared between the two groups. Results After the treatment, the total effective rate of the trial group was 91.84%, which was significantly higher than that of the control group (68.89%, P<0.05). The asthma improvement time was (8.15±2.26) days, the cough improvement time was (8.02±2.10) days, the wet arpeggio improvement time was (8.16±1.25) days, the respiratory improvement time was (49.69±6.11) hours, and the purpura improvement time was (35.29±6.52) hours of the trial group, which were significantly shorter than those of the control group , and there were significant differences (all P<0.05). Before the treatment, there were no significant differences between the two groups in the PCO2 and OI values (P>0.05). After the treatment, the PCO2 value of the trial group was significantly lower than that of the control group, but the OI value of the trial group was significantly higher than that of the control group (both P<0.05). Conclusion The application of budesonide aerosol combined with ambroxol injection in the treatment of neonatal pneumonia has significant curative effect. It can significantly shorten the improvement time of clinical symptoms and improve the respiratory indexes, so it is worthy of promotion.